M. A. N. ŞENDUR Et Al. , "Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer," Current Medical Research and Opinion , vol.31, no.3, pp.547-556, 2015
ŞENDUR, M. A. N. Et Al. 2015. Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer. Current Medical Research and Opinion , vol.31, no.3 , 547-556.
ŞENDUR, M. A. N., AKSOY, S., YORGUN, H., Ozdemir, N., Yilmaz, F. M., Yazici, O., ... Zungun, C.(2015). Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer. Current Medical Research and Opinion , vol.31, no.3, 547-556.
ŞENDUR, MEHMET Et Al. "Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer," Current Medical Research and Opinion , vol.31, no.3, 547-556, 2015
ŞENDUR, MEHMET A. Et Al. "Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer." Current Medical Research and Opinion , vol.31, no.3, pp.547-556, 2015
ŞENDUR, M. A. N. Et Al. (2015) . "Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer." Current Medical Research and Opinion , vol.31, no.3, pp.547-556.
@article{article, author={MEHMET ALİ NAHİT ŞENDUR Et Al. }, title={Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer}, journal={Current Medical Research and Opinion}, year=2015, pages={547-556} }